hotspot -WSS

hotspot

author：leisure time 2025-09-28 01:36:14 - browse：79

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： How one medical school became remarkably diverse
Next article： Is mRNA technology the right fit for flu shots? Experts aren’t so sure

knowledge

Wikipedia

WSS

CDC director unscathed in first congressional testimony

What don’t we know about an Alzheimer’s drug side effect?

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

J&J to emphasize cancer drugs, stop much of its vaccine research

How to pay for weight loss drugs and save Medicare

Creating egg and sperm cells from stem cells raises ethical issues

knowledge

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

30 years of 'Listening to Prozac'

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Plastic surgeons increase patient psychiatric screenings

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

J&J to emphasize cancer drugs, stop much of its vaccine research

After affirmative action ruling, medical educators look to 'holistic review'

Leading voice in opioid treatment defends methadone clinic system

Malaria cases in Florida and Texas: Here’s what you need to know

What to do when lifesaving products contribute to climate change

focus

Orchard's therapy for neuron disease in children wins FDA approval

App could help diagnose ear infections more accurately — and at home

Virtual Event: March of the Biosimilars

5 to watch: Tech startups trying to solve health care's staffing crisis

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

5 to watch: Tech startups trying to solve health care's staffing crisis

knowledge

Wikipedia

focus

hotspot